Yi I. Ba

Peking Union Medical College Hospital
Beijing, 100010, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 219 publications

Assessing Graded Histological Regression as Basis for Treatment Modification after Neoadjuvant Therapy in LAGC: An Exploratory Phase II Study.

Assessing Graded Histological Regression as Basis for Treatment Modification after Neoadjuvant Therapy in LAGC: An Exploratory Phase II Study.

Journal: Annals of surgical oncology

Published: April 13, 2026

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.

Journal: Lancet (London, England)

Published: April 08, 2026

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study.

Journal: EClinicalMedicine

Published: January 22, 2026

Cellular Senescence in Gastric Cancer: Molecular Mechanisms, Microenvironment Remodeling and Therapeutic Implications.

Cellular Senescence in Gastric Cancer: Molecular Mechanisms, Microenvironment Remodeling and Therapeutic Implications.

Journal: Aging and disease

Published: December 25, 2025

The histone demethylase KDM4A promotes esophageal cancer progression by epigenetically activating LRG1-mediated TGF-β signaling.

The histone demethylase KDM4A promotes esophageal cancer progression by epigenetically activating LRG1-mediated TGF-β signaling.

Journal: Apoptosis : an international journal on programmed cell death

Published: December 21, 2025

A Multinational, Retrospective, Real-World Study: Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Beyond First-line in East Asia (HER2+ GASTA Study).

A Multinational, Retrospective, Real-World Study: Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Beyond First-line in East Asia (HER2+ GASTA Study).

Journal: Cancer research and treatment

Published: December 05, 2025

Methyltransferase-like 3/14-mediated m6A Silencing of GPx3 Drives Lipophagy Dysfunction and Ferroptosis Resistance in Colorectal Cancer.

Methyltransferase-like 3/14-mediated m6A Silencing of GPx3 Drives Lipophagy Dysfunction and Ferroptosis Resistance in Colorectal Cancer.

Journal: Research (Washington, D.C.)

Published: December 02, 2025

Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.

Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.

Journal: Journal of gastroenterology

Published: November 24, 2025

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 05, 2025

[68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial.

[68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 31, 2025

Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report.

Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report.

Journal: Chinese clinical oncology

Published: October 13, 2025

Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer.

Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer.

Journal: Anti-cancer drugs

Published: August 14, 2025

Showing 1-12 of 219

Last Updated: 09/26/2026